H1 2020 Pipeline Review on Huntington Disease – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Huntington Disease – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington’s disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

The publisher’s Pharmaceutical and Healthcare latest pipeline guide Huntington Disease – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 13, 62, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 3 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. (Read more…) Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Huntington Disease – Overview
• Huntington Disease – Therapeutics Development
• Huntington Disease – Therapeutics Assessment
• Huntington Disease – Companies Involved in Therapeutics Development
• Huntington Disease – Drug Profiles
• Huntington Disease – Dormant Projects
• Huntington Disease – Discontinued Products
• Huntington Disease – Product Development Milestones
• Appendix

Companies Mentioned

• Acen Regenerative Medicine Sci-Tech Co Ltd
• AcuraStem Inc
• Adeptio Pharmaceuticals Ltd
• AFFiRiS AG
• Alkermes Plc
• Allianz Pharmascience Ltd
• Alsonex Pty Ltd
• Anima Biotech Inc
• Annexon Inc
• Armgo Pharma Inc
• ArunA Biomedical Inc
• Asdera LLC
• Asklepios BioPharmaceutical Inc
• Avergen Pharmaceuticals GmbH
• Azevan Pharmaceuticals Inc
• BrainStorm Cell Therapeutics Inc
• Brainvectis SAS
• Celon Pharma SA
• Chaperone Pharma BV
• Chaperone Therapeutics Inc
• Chong Kun Dang Pharmaceutical Corp
• Cleave Therapeutics Inc
• Collaborative Medicinal Development LLC
• Curyx Bio Inc
• DanPET AB
• Dystrogen Therapeutics SA
• Emerald Health Sciences Inc
• Enzerna Biosciences LLC
• Evotec SE
• Exicure Inc
• F. Hoffmann-La Roche Ltd
• Genervon Biopharmaceuticals LLC
• Hope Biosciences LLC
• Immungenetics AG
• InnoMedica Holding AG
• Krisani Bio Sciences Pvt Ltd
• Living Cell Technologies Ltd
• Locana Inc
• Medesis Pharma SA
• MindImmune Therapeutics Inc
• Mitochon Pharmaceuticals Inc
• Mitoconix Bio Ltd
• Mitokinin LLC
• MMJ International Holdings Corp
• NeuBase Therapeutics Inc
• NeuExcell Therapeutics Inc
• Neurimmune Holding AG
• Neurodon LLC
• NeuroNascent Inc
• New World Laboratories Inc
• NLS Pharma Group
• Novartis AG
• Nuredis Inc
• And Many More Companies!

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w6xazx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900